Stockscreener 앱 받기
3.73
8.35%
-0.34
시장 영업 전:
3.73
전일 마감가:
$4.07
열려 있는:
$4.07
하루 거래량:
1.99M
Relative Volume:
1.10
시가총액:
$352.29M
수익:
$829.00M
순이익/손실:
$-399.90M
주가수익비율:
-0.8642
EPS:
-4.3159
순현금흐름:
$-23.20M
1주 성능:
-9.25%
1개월 성능:
-18.74%
6개월 성능:
-41.26%
1년 성능:
-9.25%
1일 변동 폭
$3.73
$4.07
1주일 범위
$3.73
$4.44
52주 변동 폭
$3.73
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
명칭
Myriad Genetics Inc
전화
801-584-3600
주소
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, WAT, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
3.73 | 384.40M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
446.03 | 170.69B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
165.99 | 117.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.68 | 42.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
334.93 | 34.57B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.74 | 31.91B | 7.07B | 1.29B | 993.00M | 4.5355 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-21 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 개시 | Craig Hallum | Buy |
| 2024-12-10 | 개시 | UBS | Neutral |
| 2024-12-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Underperform |
| 2024-05-08 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 재개 | Piper Sandler | Neutral |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Underweight |
| 2023-05-23 | 업그레이드 | Goldman | Sell → Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 개시 | Stephens | Equal-Weight |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Sell |
| 2019-09-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-07-29 | 다운그레이드 | Needham | Strong Buy → Hold |
| 2019-07-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-03-12 | 재확인 | Needham | Strong Buy |
| 2019-01-03 | 개시 | Needham | Strong Buy |
| 2018-11-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 개시 | Goldman | Sell |
| 2018-01-22 | 재확인 | Barclays | Equal Weight |
| 2018-01-05 | 개시 | BTIG Research | Buy |
| 2017-10-02 | 재개 | Leerink Partners | Mkt Perform |
| 2017-08-09 | 재확인 | Barclays | Equal Weight |
| 2017-02-08 | 업그레이드 | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 개시 | Deutsche Bank | Sell |
| 2016-10-10 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
모두보기
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Myriad Genetics stock (US62855J1043): Q1 2026 earnings miss and recent price drop - AD HOC NEWS
State Street (MYGN) reports 4.42M Myriad shares, 4.7% stake - Stock Titan
FirstGene Multiple Prenatal Screen launch drives engagement at ACOG2026, Myriad Genetics advances genetic care - Traders Union
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions - Barchart.com
Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock - Insider Monkey
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics expands access to MyChoice Test for prostate cancer patients in Japan - SelectScience
Myriad Genetics in record sell-off after Q1 miss - MSN
Myriad Genetics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MYGN) 2026-05-08 - Seeking Alpha
Myriad Genetics, Inc. (MYGN) Stock Analysis: Evaluating a Promising 77.94% Upside Potential - DirectorsTalk Interviews
Hereditary Cancer Testing Market Will Generate Booming Growth - openPR.com
Myriad Genetics Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Myriad Genetics Is Maintained at Hold by TD Cowen - Moomoo
Myriad Genetics to join two healthcare conferences in upcoming weeks - Traders Union
Myriad Genetics to join BofA meetings, Goldman webcast in June - Stock Titan
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences - 富途牛牛
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Myriad Genetics Bets on Growth Amid Profit Squeeze - TipRanks
Myriad Genetics (MYGN) Q1 Loss Of US$34.1 Million Reinforces Bearish Profitability Concerns - Sahm
Myriad Genetics (MYGN) reports Q1 loss, misses revenue estimates - MSN
Myriad Genetics Q1 2026 earnings preview - MSN
Myriad Genetics Q1 2026 Financial Results: Revenue Breakdown, Net Loss, and Key Financial Statements - Minichart
Myriad Genetics Price Target Cut to $6.00/Share From $7.00 by TD Cowen - Moomoo
Myriad Genetics stock in sell-off after Q1 miss (MYGN:NASDAQ) - Seeking Alpha
Financial guidance for 2026 maintained as Myriad Genetics delivers first quarter results - Traders Union
MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins - TradingView
Craig-Hallum Maintains Myriad Genetics(MYGN.US) With Buy Rating, Announces Target Price $10 - Moomoo
Myriad Genetics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
MYGN Financials: Income Statement, Balance Sheet & Cash Flow | Myriad Genetics - Stock Titan
Myriad Genetics (NASDAQ: MYGN) posts Q1 2026 loss amid higher costs and impairment - Stock Titan
Myriad Genetics Q1 2026 Earnings Call Transcript - MarketBeat
Myriad Genetics Q1 2026 slides: cancer growth offsets prenatal decline By Investing.com - Investing.com South Africa
Myriad Genetics Q1 Earnings Call Highlights - Yahoo Finance
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Plunges 14% After Q1 Earnings Beat Revenue Estimates But Miss EPS - ChartMill
Myriad Genetics Q1 2026 slides: cancer growth offsets prenatal decline - Investing.com
Earnings call transcript: Myriad Genetics Q1 2026 results show mixed performance - Investing.com India
Myriad: Q1 Earnings Snapshot - Barchart.com
Myriad Genetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Q1 2026 Myriad Genetics Inc Earnings Call Transcript - GuruFocus
MSN Money - MSN
Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2% - Barchart.com
Myriad adds FDA-approved ovarian cancer test, launches new MRD assay - Stock Titan
Myriad Genetics (NASDAQ: MYGN) Q1 2026 revenue up 2% as loss widens - Stock Titan
Myriad Genetics (NASDAQ: MYGN) CCO has shares withheld to cover RSU taxes - Stock Titan
Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Myriad Genetics introduces FirstGene Multiple Prenatal Screen at ACOG2026 with interactive experience - Traders Union
RS Investment Management's Myriad Genetics Inc(MYGN) Holding History - GuruFocus
Myriad Genetics Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Only 13% say first depression medication worked, Myriad survey finds - Stock Titan
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan - ChartMill
Myriad Genetics Inc (MYGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.14%
0.35%
자본화:
|
볼륨(24시간):